EBI announced that it has acquired Xstim, a division of Precision Medical Products focused on developing next-generation bone growth stimulation solutions.
EBI is a portfolio company of Avista Healthcare Partners. The company is focused on electrobiology innovations and bone growth stimulation technologies.
The acquisition strengthens EBI’s bone growth stimulation portfolio with a modern, wearable, non-invasive spine fusion stimulation therapy. The Xstim technology is designed to support patient comfort, ease of use, and clinical confidence.
Xstim’s therapy uses capacitively coupled electrical stimulation to support bone healing following lumbar spinal fusion. EBI said the technology is highly complementary to its broader platform of non-surgical and implantable bone healing solutions.
By adding Xstim to its portfolio, EBI is positioned to offer surgeons, patients, and care teams a broader range of clinically supported options across lumbar spinal fusion, nonunion fracture, and failed joint fusion applications.
EBI’s existing portfolio includes FDA-approved and cleared bone growth stimulation solutions used across spinal fusion, nonunion fracture, and joint fusion applications. Its products include EBI Bone Healing System, OsteoGen, OrthoPak, SpF, SpinalPak, and now Xstim.
The company said the acquisition reinforces its position as the only pure-play bone growth stimulation company and supports its mission to help physicians improve patient bone-healing outcomes.
Support: Ropes & Gray served as legal counsel to EBI. William Blair served as the exclusive financial advisor to Precision Medical Products, and Perkins Coie served as legal counsel.
KEY QUOTE:
“Our vision is clear: to be the trusted market leader in bone growth stimulation, dedicated to partnering with physicians to improve their patients’ bone healing outcomes. The addition of Xstim further supports our mission by introducing next generation products, strengthening our portfolio and expanding our R&D pipeline focused on today’s modern needs for both surgeons and patients.”
Kevin Kenny, Chief Executive Officer of EBI
